Supplemental Figure 12 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Year: 2026
Type: supplementary-materials
Abstract: Change from baseline to early-on treatment timepoint in Th17 proportions in Excellent Responders is shown
Authors: Howard L. Li, Soren Charmsaz, Chester Kao, Carlotta Pazzi, Madelena Brancati, James M. Leatherman, Luke X. Zhao, Waqar Arif, Royce P. Lee, Jeric Hernandez, Nicole E. Gross, Caroline Ellis, Christopher Thoburn, Yasser Ged, Jeannie Hoffman-Censits, Evan J. Lipson, Marina Baretti, G. Scott Chandler, Rajat Mohindra, Laura Tang, Sanjay Bansal, Aditi Guha, Elizabeth M. Jaffee, Daniel J. Zabransky, Won J. Ho, Mark Yarchoan, Mari Nakazawa
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7205003863
Cites:
Cited by:
Related to: